These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 11713766

  • 1. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J.
    Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
    [Abstract] [Full Text] [Related]

  • 2. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 3. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
    Kigawa J, Sato S, Shimada M, Kanamori Y, Itamochi H, Terakawa N.
    Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
    [Abstract] [Full Text] [Related]

  • 4. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF, Xie L, McDonald M, DiGiacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B, Nielsen LL.
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [Abstract] [Full Text] [Related]

  • 5. [Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan].
    Kagawa S, Fujiwara T, Tanaka N.
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):193-7. PubMed ID: 12610865
    [Abstract] [Full Text] [Related]

  • 6. Advances in adenovirus-mediated p53 cancer gene therapy.
    Tazawa H, Kagawa S, Fujiwara T.
    Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
    [Abstract] [Full Text] [Related]

  • 7. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR, Wang-Gohrke S, Köhler T, Kreienberg R, Runnebaum IB.
    Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
    [Abstract] [Full Text] [Related]

  • 8. [Adenoviral p53 gene therapy for human lung cancer].
    Fujiwara T, Tanaka N.
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):460-7. PubMed ID: 12722675
    [Abstract] [Full Text] [Related]

  • 9. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
    Boulay JL, Perruchoud AP, Reuter J, Bolliger C, Herrmann R, Rochlitz C.
    Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
    [Abstract] [Full Text] [Related]

  • 10. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
    Heise C, Lemmon M, Kirn D.
    Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251
    [Abstract] [Full Text] [Related]

  • 11. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer.
    Rizk NP, Chang MY, El Kouri C, Seth P, Kaiser LR, Albelda SM, Amin KM.
    Cancer Gene Ther; 1999 Dec; 6(4):291-301. PubMed ID: 10419047
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
    Song K, Cowan KH, Sinha BK.
    Oncol Res; 1999 Dec; 11(3):153-9. PubMed ID: 10527075
    [Abstract] [Full Text] [Related]

  • 15. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.
    Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL.
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):33-7. PubMed ID: 9704675
    [Abstract] [Full Text] [Related]

  • 16. Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region.
    Edelman J, Edelman J, Nemunaitis J.
    Curr Opin Mol Ther; 2003 Dec; 5(6):611-7. PubMed ID: 14755887
    [Abstract] [Full Text] [Related]

  • 17. New horizons: gene therapy for cancer.
    Baselga J.
    Anticancer Drugs; 1999 Nov; 10 Suppl 1():S39-42. PubMed ID: 10630368
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
    Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D.
    Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
    [Abstract] [Full Text] [Related]

  • 19. Restoration of tumour suppressor gene expression for cancer.
    Roth JA.
    Forum (Genova); 1998 Nov; 8(4):368-76. PubMed ID: 9863031
    [Abstract] [Full Text] [Related]

  • 20. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG.
    Adv Cancer Res; 2007 Nov; 97():321-38. PubMed ID: 17419952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.